<DOC>
	<DOC>NCT02392351</DOC>
	<brief_summary>The REDUCE HTN: REINFORCE study is being conducted to determine whether the Vessix Reduce™ Catheter and Vessix™ Generator for the treatment of uncontrolled hypertension (off-treatment office systolic blood pressure ≥150 mmHg and ≤180 mmHg) shows acceptable performance at 8 weeks when compared to a masked procedure (renal angiogram).</brief_summary>
	<brief_title>Renal Denervation Using the Vessix Renal Denervation System for the Treatment of Hypertension (REDUCE HTN:REINFORCE)</brief_title>
	<detailed_description>Prospective, multicenter, single blinded, randomized, controlled, pilot study. Subjects will be randomized to renal denervation treatment or masked renal angiogram procedure (2:1).</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<criteria>Age ≥18 and ≤75 years OSBP ≥150 mmHg and ≤180 mmHg based on an average of 3 officebased blood pressure measurements Average 24hour ASBP ≥135 mmHg and ≤170 mmHg For each kidney, a main renal artery, with or without accessory renal arteries, with diameter ≥3.0 mm and ≤7.0 mm and length ≥20.0 mm Agrees to have all study procedures performed, and is competent and willing to provide written, informed consent Stenosis &gt;30% or renal artery aneurysm in either renal artery Fibromuscular dysplasia (FMD) Known causes of secondary HTN Type 1 diabetes mellitus eGFR &lt;40 mL/min/1.73m2 Known ejection fraction of &lt;30% or heart failure that required hospitalization in the previous 6 months Severe valvular heart disease ≥1 episode(s) of orthostatic hypotension not related to medication changes (reduction of SBP of ≥20 mmHg or DBP of ≥10 mmHg within three minutes of standing) coupled with symptoms within the past year or during screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Hypertension</keyword>
	<keyword>Renal Denervation</keyword>
</DOC>